resM can say it "supports metabolism." It cannot say it "treats obesity" or "prevents diabetes." This is why you see careful language on the product page and why the product carries the standard disclaimer that it has not been evaluated by the FDA
Organizations that cover GLP-1 drugs for weight loss typically do so through one of three ways: a prescription drug within a medical plan (85%), a dedicated weight management vendor point solution (12%) or a supplemental drug rider (4%)
Tirzepatides gradual and steady effects help promote sustainable weight loss while improving overall metabolic health, making it an effective option for long-term weight management
In caso di sospetto, rivolgiti immediatamente a un pronto soccorso
Availability varies by state based on law
The scale of the planned development program signals that obesity is likely to remain a key focus for Pfizer (NYSE:PFE), which could influence where the company allocates capital, forms partnerships, and directs commercial resources over the coming years